HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

506.075

-10.940-2.12%

Number of Gainers:9

Number of Losers:21

Number of Flat:3

PE:- -

High:516.490

Open:516.490

Low:500.597

Close:517.015

Volume:149.97M

Turnover:4.87B

Market Cap:324.25B

Float Cap:288.12B

Loading ...

Huiyu Pharma's Aesthetic Medicine Expansion Stalls: Subsidiary Insolvency and Funding Model Expose Multiple Hazards

Norway's Medistim Q2 Revenue Rises on Own-Product Sales Growth

Akeso Says China NMPA Clears Phase I Trial for B7-H3 ADC Ak157d1 in Solid Tumors

Akeso's Ak157d1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline

THOMSON REUTERS

Apichope's Subsidiary Gains Regulatory Nod for Novel Drug Trial Application

Hong Kong Stock Market Flash: BRII-B Surges Over 8% as Interim Loss Narrows 32.08% and Promising Clinical Data Emerges

ZYLOXTB Surges Over 9% Intraday on Strong H1 Net Profit of 179 Million Yuan, Up 47.8% Year-On-Year

HUA MEDICINE-B (02552) Balances Stability with Progress: HuaTangNing® Commercial Expansion Paves the Way for Global Value Delivery

When This Sector Rallies, Tech Takes a Backseat

China's Brii Biosciences Interim Net Loss Narrows on Lower R&D Expenses

Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results

THOMSON REUTERS

Brii Biosciences: Hy Other Income Rmb19.5 Mln

THOMSON REUTERS

Brii Bio H1 FY26 Loss Narrows 32.1% to RMB 101 Million

Everest Medicines Limited (HKG:1952) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Simply Wall St.

CSTONE PHARMA-B Gets NMPA Green Light for CS5007 Investigational New Drug Application

SinoMab BioScience Announces Extraordinary General Meeting

CStone Says China NMPA Clears IND for Cs5007 Egfr/her3 Bispecific ADC

CStone Pharmaceuticals - Receives Nmpa Ind Approval for Cs5007 in China

THOMSON REUTERS

Keymed Biosciences (SEHK:2162) Stock Questions Whether New Profit Can Last

Simply Wall St.

Zylox-Tonbridge Delivers Strong First-Half 2026 Results as International Revenue Surges 349%

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/BK1574/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":506.0749,"timestamp":1787299686774,"preClose":517.0147,"halted":0,"volume":149966252,"delay":0,"changeRate":-0.02116,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-10.939819,"latestTime":"08-21 16:00:00","open":516.49023,"high":516.49023,"low":500.59692,"amount":4865243342.5,"amplitude":0.030741,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"pbRate":4.109535,"peRate":-81.157718,"turnoverRate":0.005372,"increases":11,"decrements":20,"flats":2,"marketCap":324245256080,"floatMarketCap":288118014384},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":516.49023,"amplitude":0.030741,"preClose":517.0147,"low":500.59692,"pbRate":"4.109535","latestPrice":506.0749,"volume":149966252,"delay":0,"open":516.49023,"prevYearClose":556.26263,"prevWeekClose":518.327,"prevMonthClose":473.313,"prevQuarterClose":453.519,"fiveDayClose":518.327,"twentyDayClose":498.407,"sixtyDayClose":542.586,"secType":"PLATE","market":"HK","turnoverRate":0.005372,"peRate":-81.157718,"marketCap":324245256080,"floatMarketCap":288118014384,"timestamp":1787299686774,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":9,"down":21,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1170961908","title":"Huiyu Pharma's Aesthetic Medicine Expansion Stalls: Subsidiary Insolvency and Funding Model Expose Multiple Hazards","url":"https://stock-news.laohu8.com/highlight/detail?id=1170961908","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170961908?lang=en_us&edition=fundamental","pubTime":"2026-08-21 14:52","pubTimestamp":1787295166,"startTime":"0","endTime":"0","summary":"Under the pressure of generic drug centralized procurement, Huiyu Pharmaceutical (688553.SH) has pinned hopes on the aesthetic medicine sector to forge a second growth curve. Yet its aesthetic...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661825746","title":"Norway's Medistim Q2 Revenue Rises on Own-Product Sales Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2661825746","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661825746?lang=en_us&edition=fundamental","pubTime":"2026-08-21 14:40","pubTimestamp":1787294458,"startTime":"0","endTime":"0","summary":"Norway's Medistim Q2 revenue rises on own-product sales growthOverviewNorway medical device maker's Q2 revenue grew 19.5% yr/yr to NOK 202 mlnQ2 operating profit (EBIT) rose 20.6% to NOK 65.3 mln, EBI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nL1N44I05U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1574","02190","BK1583","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661528902","title":"Akeso Says China NMPA Clears Phase I Trial for B7-H3 ADC Ak157d1 in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2661528902","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661528902?lang=en_us&edition=fundamental","pubTime":"2026-08-21 13:31","pubTimestamp":1787290275,"startTime":"0","endTime":"0","summary":"Akeso says China NMPA clears Phase I trial for B7-H3 ADC AK157D1 in solid tumorsAkeso secured China NMPA CDE clearance to start a Phase I trial of AK157D1, a B7-H3 antibody-drug conjugate, in advanced","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDLc1jnKH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1961090484.USD","LU2488822045.USD","LU1794554557.SGD","LU1720050803.USD","LU0417516571.SGD","LU0348735423.USD","LU0634319403.HKD","LU0348767384.USD","09926","LU0348783233.USD","LU0417516902.SGD","LU0348827113.USD","LU2778985437.USD","BK1574","LU0417516738.SGD","IE00BPRC5H50.USD","LU0540923850.HKD","LU0348825331.USD","KURE","IE00B5MMRT66.SGD","LU0348766576.USD","LU2399975544.HKD","LU0348784397.USD","LU2476274720.SGD","LU0561508036.HKD","LU2476274308.USD","IE00B543WZ88.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661252887","title":"Akeso's Ak157d1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2661252887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661252887?lang=en_us&edition=fundamental","pubTime":"2026-08-21 13:30","pubTimestamp":1787290258,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nTUA6ZY0XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0417516738.SGD","LU0634319403.HKD","LU0348767384.USD","LU0417516571.SGD","LU0348735423.USD","KURE","LU0348783233.USD","LU2778985437.USD","LU1961090484.USD","LU2476274720.SGD","LU2488822045.USD","LU0540923850.HKD","LU1794554557.SGD","09926","LU2399975544.HKD","LU0348766576.USD","LU0417516902.SGD","IE00B5MMRT66.SGD","LU0561508036.HKD","LU1720050803.USD","LU0348827113.USD","BK1574","LU0348784397.USD","IE00BPRC5H50.USD","IE00B543WZ88.USD","BK1161","LU0348825331.USD","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158851231","title":"Apichope's Subsidiary Gains Regulatory Nod for Novel Drug Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1158851231","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158851231?lang=en_us&edition=fundamental","pubTime":"2026-08-21 11:52","pubTimestamp":1787284333,"startTime":"0","endTime":"0","summary":"Apichope Pharmaceutical Group Co., Ltd. (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received approval from the National Medical Products...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK0239","IBBQ","159992","MDTX","MEDX","BMED","PSYK","300723","06978","IBBJ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179632017","title":"Hong Kong Stock Market Flash: BRII-B Surges Over 8% as Interim Loss Narrows 32.08% and Promising Clinical Data Emerges","url":"https://stock-news.laohu8.com/highlight/detail?id=1179632017","media":"Stock News","labels":["dataReport","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179632017?lang=en_us&edition=fundamental","pubTime":"2026-08-21 11:41","pubTimestamp":1787283672,"startTime":"0","endTime":"0","summary":"Shares of BRII-B (02137) climbed more than 8% before the midday break, trading up 8.16% at HK$1.06 with turnover reaching HK$52.37 million.The company released its interim results for the six months...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","VXUS","KCAI","BK1574","BK4585","02137","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108482719","title":"ZYLOXTB Surges Over 9% Intraday on Strong H1 Net Profit of 179 Million Yuan, Up 47.8% Year-On-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1108482719","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108482719?lang=en_us&edition=fundamental","pubTime":"2026-08-21 10:10","pubTimestamp":1787278248,"startTime":"0","endTime":"0","summary":"ZYLOXTB (02190) saw its shares climb more than 9% following the release of its interim results, before settling to a gain of 5.48% at 20.78 Hong Kong dollars, with turnover reaching 21.85 million...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","BK1587","02190","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110843655","title":"HUA MEDICINE-B (02552) Balances Stability with Progress: HuaTangNing® Commercial Expansion Paves the Way for Global Value Delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=1110843655","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110843655?lang=en_us&edition=fundamental","pubTime":"2026-08-21 09:28","pubTimestamp":1787275712,"startTime":"0","endTime":"0","summary":"The Hong Kong-listed innovative drug index (931787) has climbed over 10% since August, with a maximum rebound of more than 38% from its half-year low hit in early June. The current rally is primarily...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1191","02552"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165297527","title":"When This Sector Rallies, Tech Takes a Backseat","url":"https://stock-news.laohu8.com/highlight/detail?id=1165297527","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165297527?lang=en_us&edition=fundamental","pubTime":"2026-08-21 09:10","pubTimestamp":1787274639,"startTime":"0","endTime":"0","summary":"On August 19th, the U.S. Treasury Department unexpectedly decided to at least double its long-term bond repurchase program, directly pushing global yields lower. While many assumed tech stocks would...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GCmain","MEDX","159934","518880","SGCmain","GLD","06978","LNGR","SGUmain","IBBQ","NUGT","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661125866","title":"China's Brii Biosciences Interim Net Loss Narrows on Lower R&D Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2661125866","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661125866?lang=en_us&edition=fundamental","pubTime":"2026-08-21 07:14","pubTimestamp":1787267641,"startTime":"0","endTime":"0","summary":"China's Brii Biosciences interim net loss narrows on lower R&D expensesOverviewChina biotech firm's interim net loss narrowed for six months ended June 30, 2026Lower R&D and administrative expenses co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nL1N44H13O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","06855","BK1161","BK1574","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661638258","title":"Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2661638258","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661638258?lang=en_us&edition=fundamental","pubTime":"2026-08-21 07:10","pubTimestamp":1787267400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUABLCVSX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","02137","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661325830","title":"Brii Biosciences: Hy Other Income Rmb19.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2661325830","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661325830?lang=en_us&edition=fundamental","pubTime":"2026-08-21 07:02","pubTimestamp":1787266922,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nPLXMQ7KNH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1587","BK1574","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661258376","title":"Brii Bio H1 FY26 Loss Narrows 32.1% to RMB 101 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661258376","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661258376?lang=en_us&edition=fundamental","pubTime":"2026-08-21 07:01","pubTimestamp":1787266863,"startTime":"0","endTime":"0","summary":"Brii Bio H1 FY26 loss narrows 32.1% to RMB 101 millionBrii Bio posted an IFRS net loss of RMB 101 million, narrowing 32.1% from a year earlier; basic loss per share improved to RMB 0.14.Other income f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL4prdW4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1574","BK1161","02137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661256976","title":"Everest Medicines Limited (HKG:1952) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2661256976","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661256976?lang=en_us&edition=fundamental","pubTime":"2026-08-21 06:51","pubTimestamp":1787266310,"startTime":"0","endTime":"0","summary":"It's been a pretty great week for Everest Medicines Limited ( HKG:1952 ) shareholders, with its shares surging 18% to...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-limited-hkg1952-interim-results-just-came","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1952/everest-medicines-shares/news/everest-medicines-limited-hkg1952-interim-results-just-came","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1583","DECU","FEBU","RGLO","VOTE","GXDW","MDCO","01952","VGFPF","PMDE","BK1574","JOYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163462206","title":"CSTONE PHARMA-B Gets NMPA Green Light for CS5007 Investigational New Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1163462206","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163462206?lang=en_us&edition=fundamental","pubTime":"2026-08-21 06:12","pubTimestamp":1787263936,"startTime":"0","endTime":"0","summary":"CSTONE PHARMA-B (02616) has announced that the Investigational New Drug (IND) application for CS5007, an EGFR/HER3 bispecific antibody-drug conjugate (ADC) and one of the core candidates in the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NETL","IND","BK1574","02616","BK4080","ADC","BK4231","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661230661","title":"SinoMab BioScience Announces Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2661230661","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661230661?lang=en_us&edition=fundamental","pubTime":"2026-08-21 06:07","pubTimestamp":1787263657,"startTime":"0","endTime":"0","summary":"SinoMab BioScience announces extraordinary general meetingSinoMab BioScience will hold an extraordinary general meeting in Central, Hong Kong on Sept. 7, 2026.Shareholders will vote on the proposed di","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDLbFrYsr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661923056","title":"CStone Says China NMPA Clears IND for Cs5007 Egfr/her3 Bispecific ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2661923056","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661923056?lang=en_us&edition=fundamental","pubTime":"2026-08-21 06:02","pubTimestamp":1787263372,"startTime":"0","endTime":"0","summary":"CStone says China NMPA clears IND for CS5007 EGFR/HER3 bispecific ADCCStone Pharmaceuticals secured China NMPA clearance for an IND to start clinical trials of CS5007, an EGFR/HER3 bispecific ADC.The ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL2K2DjY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661305552","title":"CStone Pharmaceuticals - Receives Nmpa Ind Approval for Cs5007 in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2661305552","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661305552?lang=en_us&edition=fundamental","pubTime":"2026-08-21 06:02","pubTimestamp":1787263355,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nFWN44H1HS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02616","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661303292","title":"Keymed Biosciences (SEHK:2162) Stock Questions Whether New Profit Can Last","url":"https://stock-news.laohu8.com/highlight/detail?id=2661303292","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661303292?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:33","pubTimestamp":1787257986,"startTime":"0","endTime":"0","summary":"Keymed Biosciences stock has cooled in recent weeks, with the share price down about 10.6% over the past month even after moving into the black over the last year. Today's earnings story is all about profit, not hype. Basic earnings per share for the first half of 2026 came in at ¥4.29, flipping from losses in 2025, and trailing twelve month earnings now support a P/E of 25.4x.\nThe market is treating that P/E as a question mark. The key issue now is whether investors see this new...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-sehk2162-stock-questions-whether-new-prof","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-sehk2162-stock-questions-whether-new-prof","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1583","DECU","FEBU","RGLO","VOTE","GXDW","BK1587","VGFPF","PMDE","BK1574","02162","JOYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660233120","title":"Zylox-Tonbridge Delivers Strong First-Half 2026 Results as International Revenue Surges 349%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660233120","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660233120?lang=en_us&edition=fundamental","pubTime":"2026-08-20 23:10","pubTimestamp":1787238639,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nTUACZXYM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02190","BK1100","BK1587","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":3,"totalSize":285,"code":"91000000","status":"200"}]}}